[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
February 14, 2000

Virologic Response Associated With a Change in Protease Inhibitor Therapy

Arch Intern Med. 2000;160(3):393-394. doi:

In the report by Guardiola and colleagues,1 a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.

First Page Preview View Large
First page PDF preview
First page PDF preview